Search
Close this search box.

ASTHMA STUDY

Tezepelumab

clinical_trials_doctor

STUDY OUTLINE

The study is:

  • Approximately 3 years in duration.
  • A Phase III trial.
  • Safety and Efficacy of two dose regimens of the study drug.
  • Weekly infusions.

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at clinicaltrials@resphealth.uwa.edu.au or phone 6151 0888.

ELIGIBILITY & REQUIREMENTS

  • Aged between 18-80 with a diagnosis of asthma made by a doctor.
  • Use of two asthma inhalers daily.
  • At least two asthma flare-ups in the last 12 months.
  • Current smokers excluded.

WHAT'S INVOLVED

  • You will be required to attend up to 17 visits to Sir Charles Gairdner Hospital for approximately 16 months.

THIS CLINICAL TRIAL IS CURRENTLY CLOSED

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Scroll to Top